Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

IMPORTANT NOTICE:

1.

2.

3.

□

2 ,
2022 2022

I. KEY FINANCIAL INFORMATION

(1) Major Accounting Information and Financial Indicators

□ √ Applicable □ Not applicable

	The third quarter of 2022	Increase/ decrease for the third quarter of 2022 over same period of last year	From the beginning of the year to the end of the Reporting Period	Increase/ decrease from the beginning of the year to the end of the Reporting Period over same period of last year
[illegible]	1,636,515,303.73	7. 3%	5,3 5,177,444.06	16.4 %
[illegible]	141,11 ,351.11	14.41%	652,257, 52.66	41.33%
[illegible]	122, , ,12 .35	-0.23%	627,2 6,620.2	53.72%
[illegible]			. 71 ,2 1,0 . . 4	. 6 6.10%
[illegible]	0.0 62	14.3 %	0.4445	41.34%
[illegible]	0.0 62	14.3 %	0.4445	41.34%
[illegible]	1.14%	0.0 %	5.4 %	1.53%
	As at the end of the Reporting Period	As at the end of last year	Increase/decrease for the end of the Reporting Period over the end of last year	
[illegible]	21,46 ,0 ,221.2	1 ,10 ,175,266.7	12.36%	
[illegible]	12,361,047,4 5. 3	11,411,354,455.	.32%	

(2) Items and Amounts of Extraordinary Profits and Losses

— □

Currency: RMB Unit: Yuan

Items	Amounts from the third quarter of 2022	Amounts from the beginning of the year to the end of the Reporting Period	Description
( )	720, 70.62	65 ,736. 5	
( )	1 ,326,556. 5	32,71 , 75.34	
5 ( ) / 1 0.			

1. Balance sheet items

Items	As at the end of the Reporting Period	As at the end of last year	Year-on-year increase/ decrease	Reasons for changes
[illegible]	6,070,007.3	10,00 ,75 . 6	. 3 .36%	[illegible]
[illegible]	6,503,40 , .32	4,707,54 ,5 2.43	3 .15%	[illegible]
[illegible]	20,557,35 .51	14, . 2, 21.5	37.11%	[illegible]
[illegible]	301,261,305.2	204,063, 3 .27	47.63%	[illegible]
[illegible]	3,046, 2 , 03.75	1, 6,2 4,700.56	61.53%	[illegible]
[illegible]	4 6,111, 43.1			

q7t-s	The Reporting Period	Same period of last year	Year-on-year increase/ decrease	Reasons for changes
	1, 21,2 2.6	26,7 5, 4.6	405. 4%	
	14,746,57 .3	6, 4,547.46	114.20%	
	17,111, 17.61	11,7 5,24 . 0	45.07%	
	4,475,25 .23	2, 23,54 .16	53.0 %	
	777,1 4.3	1, 2 ,3 . 5	5 .70%	
	41, 14,322.53	560,025,657.66	50.33%	

Items	The Reporting Period	Same period of last year	Year-on-year increase/ decrease	Reasons for changes
	1,053,241.5	6,437,623.23	. 3.64%	
	41,0 5,361.37	553,666,240. 2	51. 1%	
	1 1,031,762.00	. 6,603,6 3.55	. 7.75%	
	650,063,5 . .37	457,062,547.37	42.23%	

3. Cash flow items

Items	The Reporting Period	Same period of last year	Year-on-year increase/ decrease	Reasons for changes
	. 71 ,2 1,0 . . 4	122,722,54 . 0	. 6 6.10%	

Items	The Reporting Period	Same period of last year	Year-on-year increase/ decrease	Reasons for changes
	2,353,7 0.24	1,037,327, 22.77	.77%	
	70,216,60 .77	467,723, 55.63	307.43%	
	10,5 5,0 0.37	27,3 5,4 4.60	13 .64%	
	263, 74,37 .54	664, 31,021.34	60.32%	

(, **API**–)

(, **CDMO**–)

Heparin Industrial Chain Business

4,611.3 (4,054.5).
50.2% (
43.5%) 4 . % (
56.5%)
2022,

2,315.2
31.1% 1,765.6
32.7%

26.2%
144.6%
77.5%

2,20 .6 (2,176.0),
1.5%

CDMO Business

74 (545.0).

(**Cytovance**–)

(&),

1 .5% 21.3%





II. INFORMATION OF THE SHAREHOLDERS

(1) Table of total number of ordinary shareholders, the number of preferred shareholders whose voting rights have been restored and shareholdings of the top 10 shareholders

Unit: Share(s)

Total number of ordinary shareholders as at the end of the Reporting Period		26,203	Total number of preferred shareholders (if any) whose voting rights have been restored as at the end of the Reporting Period			0
Shareholding of the top 10 shareholders						
Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Status of shares pledged, marked or frozen	
					Status of shares	Number
#		32.31%	474,02 ,..	0		
( )		27. 1%	40 ,041,2 0	0		
		14. %	21 , 4 ,4 0	0		
( )		3.16%	46,425,600	0		
		2.75%	40,320,000	0		
		1.64%	24,130,651	0		
II		1.03%	15,11 ,035	0		
		0.71%	10,46 ,72	0		
		0.27%	3,.. 7,265	0		
III		0.26%	3, 6,264	0		

Shareholding of the top 10 shareholders who are not subject to selling restrictions			
Name of shareholder	Number of shares held not subject to selling restrictions	Type of shares	
		Type of shares	Number
#	474,02 ,...		474,02 ,...
( )	40 ,041,2 0		40 ,041,2 0
(Note 1)	21 , 4 ,4 0		21 , 4 ,4 0
( )	46,425,600		46,425,600
	40,320,000		40,320,000
	24,130,651		24,130,651
	15,11 ,035		15,11 ,035
	10,46 ,72		10,46 ,72
	3,. 7,265		3,. 7,265
	3, 6,264		3, 6,264
Explanations of the related relationships or acting in concert among above shareholders	( ) ( ) ( ) 3 . % 10 (香港中央結算(代理人)有限公司)'		
Description of the top 10 shareholders' participation in financing and securities lending business (if any)	10 60,000,000 4.0 %		

(2) Statement of the total number of preferred shareholders of the Company and shareholdings of the top 10 preferred shareholders

□ —

III. OTHER IMPORTANT EVENTS

□ [illegible]

IV. QUARTERLY FINANCIAL STATEMENTS

(1) Financial Statements

1. Consolidated Balance Sheet

[illegible]

Currency: RMB Unit: Yuan

Items	September 30, 2022	[illegible] 1, 2022
Current assets:		
[illegible]	**2,947,231,848.07**	2, 44,257,0 6.12
[illegible]		
[illegible]		
[illegible]	**1,250,782,145.17**	1,157,143.06
[illegible]		
[illegible]	**6,070,007.38**	10,00 ,75 . 6
[illegible]	**1,586,989,756.41**	1,51 ,444,4 2.00
[illegible]		
[illegible]	**201,578,118.74**	1 ,230,6 .3
[illegible]		
[illegible]		
[illegible]		
[illegible]	**173,625,047.99**	243, 11,414.25
[illegible]		
[illegible]		
[illegible]		
[illegible]	**6,503,409,988.32**	4,707,54 ,5 2.43
[illegible]	**20,557,358.51**	14, 2, 21.5
[illegible]		
[illegible]		
[illegible]	**193,439,468.14**	151,201,475.27
[illegible]	**12,883,683,738.73**	10,76 ,653,462 6

Items	September 30, 2022	1, 2022
	433,516,795.52	3 5,7 6,645.07
	461,708,853.20	3 3,7 2,1 5.25
	150,212,971.31	156,261,10 .6
	119,633,284.22	15 ,71 ,60 .60
	357,096,121.20	403,221,557.47
	31,808,587.27	
	1,669,376,634.61	1,413,635,355. 3
	3,364,908.32	3,76 ,4 0.51
	6,241,738,372.13	4,7 1,46 ,653.07
Non-current liabilities:		
	1,672,602,948.04	1,3 ,037,756. 6
	496,111,943.19	62,232,161.16
	104,240,297.81	104,000,6 7.4
	339,805.72	2 7, 66.0
	69,187,918.91	13 ,020,0 . .00
	9,766,766.17	,770,665.53
	19,742,990.60	16,672,645.6
	383,481,900.37	275,35 ,306.24
	2,755,474,570.81	2,7 3,3 0,1 .14
	8,997,212,942.94	7,5 4, 5 , 51.21

Items	September 30, 2022	1, 2022
Owners' equity:		
	1,467,296,204.00	1,467,2 6,204.00
	5,916,624,759.22	5, 43,653,365.2
	192,462,995.09	1 3,356,155.51
	536,799,924.51	536,7 , 24.51
	4,247,863,603.11	3,646, 61,117.5
	12,361,047,485.93	11,411,354,455.
	110,838,792.42	111, 60, 5 .6
	12,471,886,278.35	11,523,315,415.57
	21,469,099,221.29	1 ,10 ,175,266.7

Items	Amount for current period	[illegible]
[illegible]		
[illegible]		
[illegible]	**–14,746,578.38**	6, 4,547.46
[illegible]	**–17,111,917.61**	11,7 5,24 . 0
[illegible]	**–4,475,259.23**	2, 23,54 .16
[illegible]	**777,184.39**	1, 2 ,3 . 5
[illegible]	**841,914,322.53**	560,025,657.66
[illegible]	**234,280.43**	7 ,206.4
[illegible]	**1,053,241.59**	6,437,623.23
[illegible]	**841,095,361.37**	553,666,240. 2
[illegible]	**191,031,762.00**	6,603,6 3.55
[illegible]	**650,063,599.37**	457,062,547.37
[illegible]		
1.[illegible]	**650,063,599.37**	457,062,547.37
2.[illegible]		
[illegible]		
1.[illegible]	**652,257,852.66**	461,505,654.17
2.[illegible]	**–2,194,253.29**	4,443,106. 0
[illegible]	**377,190,878.62**	2, 70,4 7.52
[illegible]	**375,819,150.60**	3,0 0,457.04
[illegible]	**49,442,159.49**	1,00 ,65 . 5

Items	Amount for current period	
1.	**56,813,153.88**	3,261,531.31
2.		
3.	**–7,370,994.39**	4,270,1 1.26
4.		
5.		
(II)	**326,376,991.11**	4,0 ,116.
1.	**14,161,222.65**	10,602,42 .21
2.		
3.		
4.		
5.		
6.	**312,215,768.46**	14,6 1,546.20
7.		
	1,371,728.02	10 , 6 .52
II	**1,027,254,477.99**	460,033,034.
(I)	**1,028,077,003.26**	464,5 6,111.21

3. Consolidated Cash Flow Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	
	5,636,346,156.36	4,701,1 0,656. 3
	375,424,510.04	276, 73,471.02
	72,009,536.97	35, , ,051.21
	6,083,780,203.37	5,014,053,17 .06
	5,322,980,702.09	3,625,4 , ,06 , 1

Items	Amount for current period	
	717,088,081.77	5 5,42 ,54 .
	211,193,118.23	1 5,176,0 3.71
	551,799,391.12	4 5,235, 27.66
	6,803,061,293.21	4, 1,330,630.26
	–719,281,089.84	122,722,54 . 0
	2,470,118,418.02	2,427,26 ,37 .42
	93,980,404.15	5 7, 1,353.51
	151,844.45	170,362.74
	2,020,354,688.99	1, 0 ,6 0,742. 0
	4,584,605,355.61	4, 25,011, 37.57
	162,563,223.26	144,755,500.41
	2,749,695,820.61	1,504,112,301.61
	1,669,992,531.50	2,23 , 16,112.7
	4,582,251,575.37	3, 7,6 3, 14. 0
	2,353,780.24	1,037,327, 22.77
	4,928,822,097.65	2, 0,440,715.27
	10,997,692.25	
	4,939,819,789.90	2, 0,440,715.27
	3,627,473,860.07	2, 3 , 17, 57.11
	209,613,269.79	3 2,0 ,306.73

Items	Amount for current period	
	132,516,051.27	36,15 ,407.06
	3,969,603,181.13	3,35 ,164,670. 0
	970,216,608.77	. 467,723, 55.63
	10,585,080.37	. 27,3 5,4 4.60
	263,874,379.54	664, 31,021.34
	1,479,633,434.04	1,330,245,256.17
	1,743,507,813.58	1, . 5,176,277.51

(2) Audit Report